Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies’ experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. and French biotech Valneva SE, this represents the formal transition from years of clinical development into European regulatory review.
The Clinical Case
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified analysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial’s predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified analysis showed 74.8% efficacy and did meet that threshold.
A Competitive Setup For Valneva
Valneva SE, the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE will benefit as a development partner.
Institutional Positioning
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. is still a strong name in the institutional space, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE, however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
The Bull Case
Being the most advanced Lyme disease vaccine candidate in clinical development implies that, if approved, the companies would have no direct competitors in a market that includes over 200 million at-risk people in Europe. A Phase 3 effectiveness rate of more than 70% and no reported safety issues provide a solid scientific foundation for the application’s evaluation by the EMA. For Valneva SE, a niche but exclusive product like this could be very significant given the company’s small size, whereas for Pfizer Inc., the vaccine adds another long-term asset to an already diversified portfolio at fairly low incremental risk.
The Bear Case
That said, MAA validation simply means that the application meets the standards for EMA to begin evaluating it, not that approval is near or even guaranteed, and formal reviews of this nature often take many months to complete. Pfizer Inc. shares were essentially flat, which implies that the market views this as an incremental, predictable step rather than a major event, which is understandable considering how small a single vaccination program is in comparison to Pfizer’s whole business. Valneva’s negligible hedge fund ownership may be an indication that institutional investors haven’t yet meaningfully priced in the vaccine’s commercial potential, which could reflect uncertainty about approval timing, future pricing and reimbursement factors in European healthcare systems, or Valneva’s ability to benefit effectively given that Pfizer, not Valneva SE, holds exclusive marketing rights.
Insider Monkey’s Verdict
For Pfizer Inc., this news is a moderate positive within a vast, diverse business, worth following but unlikely to impact its valuation substantially until an official approval decision is made. Given Valneva’s size and generally scant institutional following, the stakes are accordingly much higher, making this one of the more important near-term triggers on its calendar.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
